Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 281 results for covid-19

  1. What are the possible outcomes for people who are critically ill and have COVID-19-associated pulmonary aspergillosis (CAPA)?

    What are the possible outcomes for people who are critically ill and have COVID-19-associated pulmonary aspergillosis (CAPA)? Any...

    Research recommendation
    Published
    17 December 2021

  2. What is the clinical and cost effectiveness of budesonide for treating COVID-19 in the community in adults, young people and children?

    What is the clinical and cost effectiveness of budesonide for treating COVID-19 in the community in adults, young people and children?...

    Research recommendation
    Published
    12 November 2021

  3. Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA897)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.

    Technology appraisal guidance
    Published
    6 June 2023
    View recommendations

    Sections for TA897

  4. Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils (TA1142)

    Evidence-based recommendations on dupilumab (Dupixent) for add-on maintenance treatment of uncontrolled chronic obstructive pulmonary disease (COPD) with raised blood eosinophils in adults.

    Technology appraisal guidance
    Published
    26 March 2026
    View recommendations

    Sections for TA1142

  5. What is the efficacy and safety of COVID-specific antiviral drugs in combination with other COVID-specific antiviral drugs or COVID-specific neutralising monoclonal antibodies in people who do not need supplemental oxygen and are within 7 days of symptom onset?

    efficacy and safety of COVID-specific antiviral drugs in combination with other COVID-specific...

    Research recommendation
    Published
    9 March 2022

  6. What is the effectiveness and safety of extended pharmacological venous thromboembolism (VTE) prophylaxis for people who have been discharged after treatment for COVID-19?

    (VTE) prophylaxis for people who have been discharged after treatment for COVID-19? Any explanatory notes(if applicable) Suggested PICO...

    Research recommendation
    Published
    10 August 2021

  7. What is the effectiveness, cost effectiveness and safety of using a combination of casirivimab and imdevimab at doses other than 8 g for treating COVID-19?

    combination of casirivimab and imdevimab at doses other than 8 g for treating COVID-19? Any explanatory notes(if applicable) Suggested...

    Research recommendation
    Published
    12 November 2021

  8. Does early review and referral to specialist palliative care services improve outcomes for adults with COVID-19 thought to be approaching the end of their life?

    to specialist palliative care services improve outcomes for adults with COVID-19 thought to be approaching the end of their life? Any...

    Research recommendation
    Published
    10 August 2021

  9. In people with suspected COVID-19-associated pulmonary aspergillosis (CAPA), what are the most accurate tests for diagnosing the infection and when should they be done?

    Recommendation ID NG191/12 Question In people with suspected COVID-19-associated pulmonary aspergillosis (CAPA), what are the most...

    Research recommendation
    Published
    17 December 2021

  10. What pathophysiological mechanism(s) underlie the most common presentations of post-COVID-19 syndrome? For example, generalised fatigue, breathlessness, and “brain fog”?

    pathophysiological mechanism(s) underlie the most common presentations of post-COVID-19 syndrome? For example, generalised fatigue,...

    Research recommendation
    Published
    12 November 2021

  11. Acute respiratory infection in over 16s: initial assessment and management including virtual wards (hospital at home) (QS210)

    This quality standard covers the initial assessment and management of suspected acute respiratory infection in over 16s, including acute respiratory infection virtual wards.

    Quality standard
    Published
    31 October 2023
    View quality statements

    Sections for QS210

  12. What is the effectiveness of awake body positioning in improving outcomes for people in hospital with COVID-19 who are not intubated and have higher oxygen needs?

    awake body positioning in improving outcomes for people in hospital with COVID-19 who are not intubated and have higher oxygen needs?...

    Research recommendation
    Published
    9 March 2022

  13. What is the effectiveness and safety of standard-dose compared with intermediate-dose pharmacological venous thromboembolism (VTE) prophylaxis for people with COVID-19, with or without additional risk factors for VTE?

    pharmacological venous thromboembolism (VTE) prophylaxis for people with COVID-19, with or without additional risk factors for VTE? Any...

    Research recommendation
    Published
    10 August 2021

  14. Does a multidisciplinary team agreed approach to weaning from continuous positive airway pressure improve weaning times and result in stopping continuous positive airway pressure for people with COVID-19 and acute respiratory failure?

    result in stopping continuous positive airway pressure for people with COVID-19 and acute respiratory failure? Any explanatory notes(if...

    Research recommendation
    Published
    12 November 2021

  15. Published guidance, NICE advice and quality standards

    Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards